Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Disease Interventions and Comparators Evaluated in the Primary Economic Model

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Change in A1C From Baseline and Risk Reduction for Diabetes Complications

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Average Annual Per-Patient Cost of Diabetes Complications and Interventions in Ontario

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Cost to Patient of Technologies With Various Levels of Government Funding

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Base Case Analysis

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 1 Results a

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 2 Results

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 3 Results

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 4 Results

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 5 Results

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections

Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom b Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) 8,587 8,587 Dexcom b SMBG plus insulin pump (Animas Vibe or MiniMed Veo) 6,817 6,817 Medtronic and Animas b SMBG plus multiple daily injections 3,677 3,677 Estimate c Open in a separate window Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. a We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis.

Techniques: